Loxoribine Affects Fludarabine Activity on Freshly Isolated B-chronic Lymphocytic Leukemia Cells

References

• Gale R.P., Foon K.A. Chronic lymphocytic leukemia: recent advances in biology and treatment. Ann. Intern. Med. 1985; 103: 101–120
   PubMed Web of Science ®Google Scholar
• Linet M.S., Blattner W.A. The epidemiology of chronic lymphocytic leukemia. Chronic lymphocytic leukemia, A. Polliack, D. Catovsky. Harwood Academic Publishers, London 1988
   Google Scholar
• Baccarani M., Cavo M., Gobbi M., Lauria F., Tura S. Staging of chronic lymphocytic leukemia. Blood 1988; 59: 1191–1196
   Google Scholar
• Lee J.S., Dixon D.O., Kantarjian H.M., Keating M.J., Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987; 63: 929–936
   Google Scholar
• Galton D. A. G., Wiltshaw E., Szur L., Dacie J.V. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukemia. Br. J. Haematol. 1961; 7: 73–98
   PubMed Web of Science ®Google Scholar
• Hughley C.M., Jr. Treatment of chronic lymphocytic leukemia. Cancer Treat. Rev. 1989; 4: 261–275
   Web of Science ®Google Scholar
• Rozman C., Montsemat E. Chronic lymphocytic leukemia: when and how to treat. Blur 1990; 59: 467–472
   Google Scholar
• Liepman M., Votaw M.L. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978; 41: 1664–1669
   PubMed Web of Science ®Google Scholar
• Oken M.M., Kaplan M.E. Combination chemotherapy with cyclophosphamide, vincristine and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treat. Rep. 1979; 63: 441–447
   PubMedGoogle Scholar
• French Cooperative Group on Chronic Lymphocytic Leukaemia. Long term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. Br. J. Haematol. 1989; 73: 334–340
   PubMed Web of Science ®Google Scholar
• Dillman R.O., Mick R., McIntyre O.R. Pentostatin in chronic lymphocytic leukemia: a phase II trial of cancer and leukemia group B. J. Clin. Oncol. 1989; 7: 433–438
   PubMed Web of Science ®Google Scholar
• Tallman M.S., Hakimian D., Zanzig C., et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 1995; 13: 983–988
   PubMed Web of Science ®Google Scholar
• Keating M.J., Kantarjian H., Talpaz M. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1988; 74: 19–25
   Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Beran M., et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700
   PubMed Web of Science ®Google Scholar
• Zinzani P.L., Lauria F., Rondelli D., et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur. J. Haematol. 1993; 51: 93–97
   PubMed Web of Science ®Google Scholar
• Keating M.J., Kantarjian H., O'Brien S., et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Spriano M., Clavio M., Carrara P., et al. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. Haematologica 1994; 79: 218–226
   PubMedGoogle Scholar
• Rabinowe S.N., Soiffer R.J., Gribben J.G., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–1376
   PubMed Web of Science ®Google Scholar
• Khouri I., Keating M.J., Vriesendorp H.M., et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J. Clin. Oncol. 1994; 12: 748–758
   PubMed Web of Science ®Google Scholar
• Bastion Y., Felman P., Dumontet C., Espinouse D., Coiffier B. Intensive radiochemotherapy with peripheral blood stem cell transplantation in young patients with chronic lymphocytic leukemia. Bone Marrow Transpl. 1992; 10: 467–468
   PubMed Web of Science ®Google Scholar
• Linet M.S., Cartwright R.A. Chronic lymphocytic leukemia: epidemiology and etiologic findings. Nouv. Rev. Fr. Hematol. 1988; 30: 353–357
   PubMedGoogle Scholar
• Pope B.L., Chourmouzis E., Victorino L., MacIntyre L.P., Capetola R.J., Lau C.Y. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2. J. Immunol. 1993; 15: 3007–3017
   Google Scholar
• Goodman M.G., Reitz A.B., Chen R., Bobardt M.D., Goodman J.H., Pope B.L. Selective modulation of elements of the immune system by low molecular weight nucleosides. J. Pharmacol. Exp. Ther. 1995; 274: 1552–1557
   PubMed Web of Science ®Google Scholar
• Goodman M.G., Wormsley S.B., Spinosa J.C., Piro L.D. Loxoribine induces chronic lymphocytic leukemia cells to traverse the cell cycle. Blood 1994; 10: 3457–3464
   Google Scholar
• Zinzani P.L., Buzzi M., Farabegoli P., et al. Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells. Haematologica 1994; 79: 127–131
   PubMedGoogle Scholar
• Zinzani P.L., Tosi P., Visani G., et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am. J. Hematol. 1994; 47: 301–306
   PubMed Web of Science ®Google Scholar
• Tosi P., Visani G., Ottaviani E., Manfroi S., Zinzani P.L., Tura S. Fludarabine+Ara-C+G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8: 2076–2082
   PubMed Web of Science ®Google Scholar
• Plunkett W., Huang P., Gandhi V. Metabolism and action of fludarabine phosphate. Sem. Oncol. 1990; 17(Suppl 8)3–17
   PubMed Web of Science ®Google Scholar
• Zinzani P.L., Buzzi M., Farabegoli P., et al. Induction of “in vitro” apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells. Leuk & Lymph 1994; 13: 95–97
   PubMed Web of Science ®Google Scholar
• Visani G., Tosi P., Zinzani P., et al. FLAG (fludara-bine+high-dose cytarabine+G-CSF): an effective and tolerable protocol for the treatment of “poor risk” acute myeloid leukemia. Leukemia 1994; 8: 1842–1846
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Du M., Nowak B., Keating M.J., Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin. Cancer. Res. 1995; 1: 169–178
   PubMed Web of Science ®Google Scholar